El último fármaco experimental para la obesidad de Novo Nordisk ayudó a los pacientes a perder hasta un 24% de su peso en un pequeño estudio, mostrando su potencial como tratamiento de próxima generación en el mercado hipercompetitivo.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.